Dana Chase, MD

Dana Chase, MD, is an associate professor of obstetrics and gynecology in the Division of Gynecologic Oncology at UCLA Health.

Articles

Unmet Needs and Future Research Focus for Endometrial Cancer

November 24th 2025

Panelists discuss how addressing molecular, clinical, and access-related gaps remains essential for advancing endometrial cancer research and care.

Emerging Treatment Considerations for Endometrial Cancer

November 17th 2025

Panelists discuss how emerging therapies and biomarker-driven research are shaping the next wave of innovation in endometrial cancer treatment.

Frontline Treatment Considerations in Endometrial Cancer

November 17th 2025

Panelists discuss how evolving immunotherapy combinations and NCCN guidelines shape frontline treatment selection for advanced or recurrent endometrial cancer.

Adverse Event and Quality-of-Life Considerations in Endometrial Cancer

November 10th 2025

Panelists discuss how careful management of adverse events and quality-of-life factors optimizes the safe use of dostarlimab plus chemotherapy in endometrial cancer.

RUBY Study Survival Analysis Informs Frontline Treatment Selection

November 10th 2025

Panelists discuss how survival data from the RUBY study highlight the benefits of dostarlimab plus chemotherapy in pMMR/MSS and older patient populations with advanced endometrial cancer.

Oncology Experts Dive Into Top Data From ESMO 2025

November 4th 2025

At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.

Frontline Considerations for Immunotherapy in Endometrial Cancer

November 3rd 2025

Panelists discuss how patient and disease characteristics guide the selection of frontline immunotherapy regimens in recurrent or metastatic endometrial cancer.

Molecular Subtypes of Endometrial Cancer

November 3rd 2025

Panelists discuss how molecular testing enables precise categorization of endometrial cancer into biologically distinct subtypes that guide prognosis, therapy selection, and future research direction.

Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress

October 13th 2025

Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.

Dr Chase on the Importance of Endometrial Cancer Awareness Month

September 23rd 2025

Dana M. Chase, MD, expands on the importance of endometrial cancer awareness month, which is observed annually in September.

Patient Characteristics and Disease Factors Guide the Use of Dostarlimab in Recurrent Endometrial Cancer: With Dana M. Chase, MD

September 17th 2025

Dana M. Chase, MD, discusses the management of recurrent endometrial cancer, emphasizing the importance of biomarker profiles and previous therapies.

Dr Chase on Considering Patient Preferences for Treatment Planning in Gynecologic Oncology

April 30th 2025

Dana M. Chase, MD, discusses how patient preferences can inform treatment planning in gynecologic oncology.

Dr Chase on the Importance of QOL and PRO Measures in Gynecologic Oncology

February 1st 2025

Dana M. Chase, MD, discusses the importance of quality of life and patient-reported outcome measures in gynecologic oncology.

Dr Chase on the FDA Approval of Dostarlimab Plus Chemotherapy in Endometrial Cancer

August 30th 2024

Dana M. Chase, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.

Dr. Chase on Niraparib as Frontline Maintenance Therapy in Ovarian Cancer

April 4th 2020

Dana Chase, MD, discusses niraparib as frontline maintenance therapy in ovarian cancer.

Dr. Chase on the Standard of Care for Uterine Leiomyosarcoma

May 9th 2018

Dana Chase, MD, gynecologic oncologist, Arizona Oncology, discusses the standard of care for the treatment of patients with uterine leiomyosarcoma.

Dr. Chase on the Presentation of Uterine Sarcomas

April 18th 2018

Dana Chase, MD, gynecologic oncologist, Arizona Oncology, discusses the presentation of uterine sarcomas.